Heart failure treatment company Impulse Dynamics reported on Thursday the receipt of approval from the US Food and Drug Administration for its first-in-class Optimizer Smart System designed to address a significant unmet medical need in heart failure.
Following the US FDA's Breakthrough Device designation in 2015, the Optimizer Smart System was the first breakthrough device to go before the Circulatory System Devices Panel of the US FDA's Medical Devices Advisory Committee and received the 12-0 vote on the benefit-to-risk ratio of the device.
The company said the Optimizer Smart System is the first and only CCM (Cardiac Contractility Modulation) device approved by the US FDA to improve six minute hall walk distance, quality of life and functional status of NYHA Class III heart failure patients who remain symptomatic despite guideline directed medical therapy.
CCM is a unique electrical pulse delivered during the absolute refractory period, which is just after the heart contracts. In contrast to a pacemaker or defibrillator, CCM works by modulating the strength of the heart muscle contraction rather than the rhythm.
According to the company's CEO Dr Simos Kedikoglou, Optimizer Smart System will be launched in the US later this year.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML